中文 English

Jiangli Zhang, CEO of Singlera Genomics, Presents at the 2nd Session of the Fudan Science and Innovation Forum at Fudan University

Opportunities and Challenges in Precision Medicine
December 17, 2016 – Shanghai, China
The 2016 Fudan Science and Innovation Forum was hosted by Fudan University in Shanghai, China and sponsored by Zhongzhi Enterprise Group. The Forum aims to contribute to building Shanghai as a center of technological innovation with global influence by establishing a global platform for data exchange and sharing, and by focusing on the frontiers of technology and innovation. The Forum is composed of the following four sub-forums: Artificial Intelligence, Big Data, Biomedical and Pharmaceutical Innovation and Entrepreneurship, and Developmental Genetics and Evolutionary Biology.
Over 400 invited international guests from academia, industry and government attended the Forum. Speakers included Nobel Laureate in Physics Zhaozhong Ding (MIT), Nobel Laureate in Chemistry Roger D. Kornberg (Stanford University), Dirac prize winner Shoucheng Zhang (Stanford University), expert in artificial intelligence Michael I. Jordan (UC Berkeley) and immunologists James Allison (MD Anderson Cancer Center) and Tasuku Honjo (Kyoto University). The presentations focused on the frontiers of global technology and innovation trends.
Presenters during the Biomedical and Pharmaceutical Innovation and Entrepreneurship sub-forum included Qiyu Chen, Chairman of Fosun Pharmaceutical, Qing Yang, Executive Vice President and COO of Wuxi Apptec Co. Ltd., Jiangli Zhang, co-founder and CEO of Singlera Genomics, and Haibo Wang, Chairman, Executive Director, and General Manager of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical. The presenters shared the exciting biomedical innovations from each of their companies.
Jiangli Zhang, CEO of Singlera Genomics, presented the lecture “Opportunities and Challenges in Precision Medicine” during which he shared Singlera Genomic’s latest news of advancements in precision medicine and high-throughput sequencing and discussed intelligent medical innovation and bio-medical costs. He commented that compared with the U.S., the state of cancer treatment in China is more severe. Precision medicine is new in China and is faced with the challenges of data standardization and sharing. In addition, the cost is too high to be accepted by the general population. However, he discussed the many opportunities available. The patented advanced techniques Singlera Genomics has developed will effectively solve the problem of applying precision medicine in hospitals. Moreover, the patented methylation sequencing technique specific to circulating tumor DNA offers a valuable solution to early screening for cancer with the future prospect of clinical application and value.

返 回